Select a Country Careers Partnerships Investors Newsroom
PARTNERSHIPS LICENSING AREAS OF INTEREST PROCESS OVERVIEW submit opportunity
INVESTORS INVESTOR RESOURCES REPORTS & FINANCIALS STOCK Information EVENTS & PRESENTATIONS Corporate Governance
Newsroom Press Releases Media Contacts

AbbVie Declares Quarterly Dividend

Sep 19, 2013

NORTH CHICAGO, Ill., Sept. 19, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.40 per share. 

The cash dividend is payable Nov. 15, 2013 to stockholders of record at the close of business on Oct. 15, 2013.

AbbVie was named to the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. AbbVie was included as a result of the Index's change in its treatment of spin-off companies.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott.  The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.  In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.  For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.  Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Media:

Adelle Infante
(847) 938-8745

Investors:

Liz Shea
(847) 935-2211

SOURCE AbbVie

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?